LONDON, March 4 (Reuters) - The blockbuster cancer drug Rituxan, or MabThera, can significantly reduce kidney inflammation in some people with lupus who do not respond to conventional therapy, researchers said on Wednesday.
LONDON, March 4 (Reuters) - The blockbuster cancer drug Rituxan, or MabThera, can significantly reduce kidney inflammation in some people with lupus who do not respond to conventional therapy, researchers said on Wednesday.
